Advertisement
News
Advertisement

Medtronic lands CE Mark for Viva/Brava

Mon, 08/20/2012 - 4:54pm
Mass Device

Medtronic lands CE Mark approval in the European Union for its Viva/Brava line of defibrillators that adapt to patients' cardiac rhythms.

Medtronic

Medtronic (NYSE:MDT) said it won CE Mark approval from the European Union for its Viva/Brava line of cardiac rhythm management devices.

The medical device company said the Viva and Brava products, which are cardiac resynchronization therapy with defibrillation devices, feature a new algorithm it calls AdaptivCRT designed to optimize their CRT-D treatment.

The software helped reduce right ventricular pacing by 44%, reducing unnecessary treatment and prolonging the life of the devices, according to a press release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading